4//SEC Filing
Clayman Michael D. 4
Accession 0001209191-21-017207
CIK 0001419600other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 6:16 PM ET
Size
10.2 KB
Accession
0001209191-21-017207
Insider Transaction Report
Form 4
Clayman Michael D.
DirectorPresident and CEO
Transactions
- Award
Common Stock
2021-03-01+106,100→ 373,001 total - Award
Performance Restricted Stock Unit Award
2021-03-01+159,150→ 159,150 totalExercise: $0.00→ Common Stock (159,150 underlying)
Holdings
- 347,908(indirect: By Trust)
Common Stock
- 24,600(indirect: By Trust)
Common Stock
- 388,683(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
- [F2]Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- [F3]Represents the maximum number of shares deliverable under the performance restricted stock unit award.
- [F4]Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales and certain clinical development milestones are achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025.
Documents
Issuer
Flexion Therapeutics Inc
CIK 0001419600
Entity typeother
Related Parties
1- filerCIK 0001597407
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 6:16 PM ET
- Size
- 10.2 KB